
Conference Coverage
Latest Content

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Plozasiran gains FDA approval as the first treatment for familial chylomicronemia syndrome based on phase 3 PALISADE data.

The FDA approved epcoritamab with rituximab and lenalidomide for relapsed follicular lymphoma, offering a promising fixed-duration treatment option for patients after their first relapse.

Women under 50 who consume high levels of ultraprocessed foods have a higher risk of developing early-onset conventional colorectal adenomas.

Lower-income countries rarely gain timely access to FDA-approved drugs tested in their populations, highlighting major global and ethical disparities.

Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine.

Targeted financing, clinician recruitment, and telehealth expansion are needed to improve rural primary care.

Guselkumab significantly inhibited structural joint damage and improved symptoms in active PsA through 48 weeks.

Infectious disease was hit hardest by funding cuts to NIH grant for clinical trials that did not align with the Trump administration's priorities.

Cuts to Medicaid could spell trouble for pediatric health, as millions of children rely on Medicaid to cover their hospital expenses.

Research challenges age cut-offs in AML treatment, advocating for flexible, individualized approaches based on continuous age assessment.




































































